Patent ID: 8445198

Claim:
A method of determining sensitivity of a cancer patient to a treatment for cancer comprising contacting a sample comprising one or more nucleic acid molecules from said patient to a device comprising single-stranded oligonucleotides, wherein at least one of said oligonucleotides comprises a sequence that is substantially complementary to or substantially identical to at least 15 consecutive nucleotides of a first microRNA selected from mir-142-prec or a product of a first gene selected from ZNFN1A1, and measuring hybridization between said nucleic acid molecules from said patient and said single-stranded oligonucleotides of said device to determine a level of expression of at least said first microRNA or said first gene in a cell of said patient, wherein an increase or decrease in the level of expression of said first microRNA or said first gene in said cell of said patient, relative to the level of expression of said first microRNA or said first gene in a control cell sensitive to said treatment, indicates said cell is sensitive to said treatment.